118
Participants
Start Date
December 6, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Telitacicept 240mg
Patients in telitacicept group will be treated with maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) combined with telitacicept. 240 mg telitacicept will be used once a week for 40 weeks.
Glucocorticoid
Patients in glucocorticoid group will be treated with ACEI/ARB and glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d). After 8 weeks, reduce the dosage by 5 mg per month for a total of 28-40 weeks.
RECRUITING
Ruijin Hospital, Shanghai
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
RenJi Hospital
OTHER
Sichuan Provincial People's Hospital
OTHER
Renmin Hospital of Wuhan University
OTHER
Shanghai 6th People's Hospital
OTHER
Shanghai Longhua Hospital
UNKNOWN
Huashan Hospital
OTHER
Shanghai Changzheng Hospital
OTHER
Wannan Medical College Yijishan Hospital
OTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine
OTHER_GOV
Ruijin Hospital
OTHER